Evidence map›Paper›PMID 34997121›Full record

SynthesisScientific reports2022

Meta-analysis of whole-genome gene expression datasets assessing the effects of IDH1 and IDH2 mutations in isogenic disease models.

Hans-Juergen Schulten, Fatima Al-Adwani, Haneen A Bin Saddeq, Heba Alkhatabi, Nofe Alganmi, Sajjad Karim, Deema Hussein, Khalid B Al-Ghamdi, Awatif Jamal, Jaudah Al-Maghrabi and 1 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis: A Meta-analysis.International journal of molecular and cellular medicine · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hans-Juergen SchultenCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia. hschult2@msn.com.
Fatima Al-AdwaniCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia.
Haneen A Bin SaddeqDepartment of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Heba AlkhatabiCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia.
Nofe AlganmiCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia.
Sajjad KarimCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia.
Deema HusseinKing Fahad Medical Research Center, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Khalid B Al-GhamdiDepartment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Awatif JamalDepartment of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Jaudah Al-MaghrabiDepartment of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed H Al-QahtaniCenter of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 80216, Jeddah, 21589, Saudi Arabia.
King Abdulaziz University · SAKing Faisal Specialist Hospital & Research Centre · SA

Funding

King Abdulaziz City for Science and Technology 13-BIO2289-03King Abdulaziz University 13-BIO2289-03
6 · The paper itself

Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are oncogenic drivers to a variable extent in several tumors, including gliomas, acute myeloid leukemia (AML), cholangiocarcinoma, melanoma, and thyroid carcinoma. The pathobiological effects of these mutations vary considerably, impeding the identification of common expression profiles. We performed an expression meta-analysis between IDH-mutant (IDH

Indexed as

AnimalsDisease Models, AnimalGene Expression Regulation, NeoplasticHumansIsocitrate DehydrogenaseMiceMutationProtein Interaction MapsIDH1 protein, humanIdh1 protein, mouseIDH2 protein, humanIsocitrate Dehydrogenaseisocitrate dehydrogenase 2, mouse

Identifiers

PMID34997121
PMCPMC8741954
OpenAlexW4206310070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.